guanosine-5'-monophosphate | 802582-24-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: guanosine-5'-monophosphate
• 英文别名: Guanosin-5'-α+-β-monophosphat；2-amino-9-(O⁵-phosphono-ξ-D-ribofuranosyl)-1,9-dihydro-purin-6-one；[(2R,3S,4R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 802582-24-7
• 化学式: C₁₀H₁₄N₅O₈P
• 分子量: 363.224
• InChiKey: RQFCJASXJCIDSX-LZGMGDPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• [EN] MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING<br/>[FR] ANALOGUES DE COIFFES ARNM ET PROCÉDÉS DE COIFFAGE D'ARNM
  申请人：MODERNATX INC

  公开号：WO2017066793A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

  本公开涉及公式（I）中定义的帽子类似物，其可以导致高水平的帽子效率和转录以及改善的翻译效率。本公开还涉及用于制备帽子类似物和使用包含此类类似物的mRNA物种的方法，以及包含新型帽子类似物的试剂盒。
• MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING
  申请人：ModernaTX, Inc.

  公开号：US20190225644A1

  公开（公告）日：2019-07-25

  The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
• [EN] MRNA CAP ANALOGS WITH MODIFIED SUGAR<br/>[FR] ANALOGUES DE COIFFE D'ARNM AVEC SUCRE MODIFIÉ
  申请人：MODERNATX INC

  公开号：WO2017066789A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.